---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-26-000077"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2026-09-09T12:33:41+00:00"
generated_at: "2026-09-09T12:35:08.075216+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xeris details XP-8121 Phase 3 plan; expects $1-3B peak revenue, launch in 2030

## Summary
- Phase 3 Cornerstone study: 500 patients, 1:1 vs oral levothyroxine, 54 weeks, primary endpoint TSH normal at weeks 48/54.
- Topline results expected late 2028; FDA approval and launch anticipated 2030.
- Peak net revenue potential $1-3 billion for once-weekly subcutaneous levothyroxine.
- Additional studies: pediatric (Capstone), special population (Touchstone), real-world evidence.
- KOL Dr. David Robertson to serve as Cornerstone investigator.

## SEC filing metadata
- accession: 0001867096-26-000077
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2026-09-09T12:33:41+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709626000077/0001867096-26-000077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709626000077/xers-20260909.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-26-000077
- JSON: https://secwatch.observer/filing/0001867096-26-000077.json
- Plain text: https://secwatch.observer/filing/0001867096-26-000077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.